22.99

1.95% +0.37

Arrowhead Pharmaceuticals Inc. (ARWR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché ARWR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$22.62

Aprire:

$22.72

Volume 24 ore:

321.76K

Capitalizzazione di mercato:

$2.88B

Reddito:

$181.74M

Utile/perdita netta:

$-296.81M

Rapporto P/E:

-13.44

EPS:

-1.71

Flusso di cassa netto:

$-402.70M

1 W Prestazione:

-0.99%

1M Prestazione:

-18.34%

6M Prestazione:

-10.59%

1 anno Prestazione:

-35.44%

Intervallo 1D:

$22.72

$23.56

Portata 52W:

$20.67

$42.48

Arrowhead Pharmaceuticals Inc. Stock (ARWR) Company Profile

Nome

Arrowhead Pharmaceuticals Inc.

Settore

Healthcare (1202)

Industria

Biotechnology (682)

Telefono

626-304-3400

Indirizzo

225 South Lake Avenue, Suite 1050, Pasadena, CA

Dipendente

Cinguettio

@ArrowheadPharma

Prossima data di guadagno

2024-05-16

Ultimi documenti SEC

ARWR's Discussions on Twitter

Arrowhead Pharmaceuticals Inc. Stock (ARWR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-04	Iniziato	BofA Securities	Buy
2023-09-19	Iniziato	Citigroup	Neutral
2023-07-21	Iniziato	TD Cowen	Outperform
2023-05-12	Downgrade	SVB Securities	Outperform → Market Perform
2023-04-26	Iniziato	SMBC Nikko	Outperform
2023-04-12	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-05-11	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-01-19	Ripresa	Goldman	Buy
2021-08-06	Reiterato	Chardan Capital Markets	Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-02-05	Reiterato	H.C. Wainwright	Buy
2020-12-21	Downgrade	Robert W. Baird	Outperform → Neutral
2020-12-16	Iniziato	UBS	Buy
2020-11-19	Iniziato	Citigroup	Buy
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-05-08	Aggiornamento	Oppenheimer	Perform → Outperform
2020-04-15	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-03-24	Aggiornamento	SVB Leerink	Underperform → Mkt Perform
2020-03-17	Iniziato	Goldman	Neutral
2020-01-21	Iniziato	SVB Leerink	Underperform
2019-12-13	Iniziato	Oppenheimer	Perform
2019-11-29	Reiterato	Chardan Capital Markets	Buy
2019-11-27	Reiterato	B. Riley FBR	Buy
2019-11-25	Aggiornamento	Robert W. Baird	Neutral → Outperform
2019-10-24	Downgrade	Robert W. Baird	Outperform → Neutral
2019-10-22	Reiterato	Chardan Capital Markets	Buy
2019-10-03	Iniziato	Robert W. Baird	Outperform
2018-09-07	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-09-06	Reiterato	Chardan Capital Markets	Buy
2018-08-08	Reiterato	Cantor Fitzgerald	Overweight
2018-07-02	Reiterato	Chardan Capital Markets	Buy

Mostra tutto

Arrowhead Pharmaceuticals Inc. Borsa (ARWR) Ultime notizie

NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling

Benzinga

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

Benzinga

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Benzinga

Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma

Benzinga

Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday

Benzinga

Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Arrowhead Pharmaceuticals Inc. Azioni (ARWR) Dati Finanziari

Arrowhead Pharmaceuticals Inc. (ARWR) Reddito 2024

ARWR ha riportato un ricavo (TTM) di $181.74 milioni per il trimestre terminato il 2023-12-31, un -34.71% declino anno su anno.

Arrowhead Pharmaceuticals Inc. (ARWR) Reddito netto 2024

ARWR l'utile netto (TTM) è stato di -$296.81 milioni per il trimestre terminato il 2023-12-31, un -92.09% diminuire anno su anno.

Arrowhead Pharmaceuticals Inc. (ARWR) Flusso di cassa 2024

ARWR ha registrato un flusso di cassa disponibile (TTM) di -$402.70 milioni per il trimestre conclusosi con 2023-12-31, un -70.45% diminuire anno su anno.

Arrowhead Pharmaceuticals Inc. (ARWR) Utile per azione 2024

L'utile per azione (TTM) di ARWR è stato pari a -$2.77 per il trimestre terminato il 2023-12-31, un -88.44% declino anno su anno.

Arrowhead Pharmaceuticals Inc. Azioni (ARWR) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Lu Hongbo	Director	Mar 20 '24	Buy	27.50	1,000	27,500	33,680
Lu Hongbo	Director	Mar 19 '24	Buy	28.00	1,000	28,000	32,680
Lu Hongbo	Director	Mar 18 '24	Buy	27.49	1,000	27,490	31,680
Myszkowski Kenneth Allen	Chief Financial Officer	Mar 06 '24	Sale	35.19	40,000	1,407,600	400,600
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Option Exercise	14.54	57,499	836,035	3,772,547
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Sale	32.35	57,499	1,860,019	3,715,048
Hamilton James C	Chief Discovery/Trans Medicine	Jan 12 '24	Sale	36.89	7,940	292,904	210,851
Vakiener Victoria	Director	Jan 11 '24	Sale	38.10	4,720	179,813	32,001
Waddill William D.	Director	Jan 11 '24	Sale	38.07	3,934	149,759	47,870
Ferrari Mauro	Director	Jan 11 '24	Sale	38.06	3,147	119,787	60,778